Johnson & Johnson JNJ
News
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients
Lawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in Purdue
Johnson & Johnson Completes Acquisition of Proteologix, Inc.
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease
More than 60 Law Firms Oppose J&J Prepack Bankruptcy Scheme
Johnson & Johnson Sees Positive Trial Results for Tremfya
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction
Beasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc Products
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer
Late-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 study
TALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma
Xencor: J&J's Janssen Termintates Rights to Plamotamab
Talc Plaintiffs File Motion for Temporary Restraining Order to Limit Johnson & Johnson’s Use of Bankruptcy Strategy
Johnson and Johnson Talcum-Settlement Consent Judgments Filed — Update
J&J Talcum-Settlement Consent Judgments Filed, U.S. State AGs Say
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
Johnson & Johnson Completes Acquisition of Shockwave Medical
Sarepta Therapeutics Set to Join S&P MidCap 400